NASDAQ:PLXP - PLx Pharma Stock Price, Price Target & More

$4.10 +0.15 (+3.80 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$4.10
Today's Range$3.95 - $4.15
52-Week Range$3.20 - $9.41
Volume3,415 shs
Average Volume16,250 shs
Market Capitalization$37.52 million
P/E Ratio-2.10
Dividend YieldN/A
Beta1.92

About PLx Pharma (NASDAQ:PLXP)

PLx Pharma logoPLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. Its lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. The company's product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation; and Aspertec 81 mg, a novel formulation of aspirin, which is in late-stage development. The company was founded in 2002 and is headquartered in Houston, Texas.

Receive PLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for PLXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PLXP
CUSIPN/A
Phone713-842-1249

Debt

Debt-to-Equity Ratio1.51%
Current Ratio14.19%
Quick Ratio14.06%

Price-To-Earnings

Trailing P/E Ratio-2.10
Forward P/E Ratio-2.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$780,000.00
Price / Sales45.89
Cash FlowN/A
Price / CashN/A
Book Value$0.53 per share
Price / Book7.74

Profitability

EPS (Most Recent Fiscal Year)($1.95)
Net Income$-15,340,000.00
Net MarginsN/A
Return on Equity-113.26%
Return on Assets-46.16%

Miscellaneous

Employees14
Outstanding Shares8,730,000

How to Become a New Pot Stock Millionaire

PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

How were PLx Pharma's earnings last quarter?

PLx Pharma (NASDAQ:PLXP) released its quarterly earnings results on Friday, March, 23rd. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.07. The biotechnology company had revenue of $0.34 million for the quarter. View PLx Pharma's Earnings History.

What price target have analysts set for PLXP?

3 brokerages have issued 1 year price targets for PLx Pharma's stock. Their forecasts range from $12.00 to $14.00. On average, they anticipate PLx Pharma's share price to reach $13.00 in the next twelve months. View Analyst Ratings for PLx Pharma.

Who are some of PLx Pharma's key competitors?

Who are PLx Pharma's key executives?

PLx Pharma's management team includes the folowing people:
  • Mr. Michael J. Valentino, Exec. Chairman (Age 64)
  • Ms. Natasha Giordano, Chief Exec. Officer, Pres and Director (Age 58)
  • Mr. Gary L. Mossman, Sr. Advisor (Age 77)
  • Mr. Ronald R. Zimmerman, Founder and Sr. Advisor (Age 65)
  • Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 50)

When did PLx Pharma IPO?

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

Has PLx Pharma been receiving favorable news coverage?

News headlines about PLXP stock have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. PLx Pharma earned a news impact score of 0.21 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.41 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $4.10.

How big of a company is PLx Pharma?

PLx Pharma has a market capitalization of $37.52 million and generates $780,000.00 in revenue each year. The biotechnology company earns $-15,340,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. PLx Pharma employs 14 workers across the globe.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]


MarketBeat Community Rating for PLx Pharma (PLXP)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PLx Pharma (NASDAQ:PLXP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for PLx Pharma in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 217.07%. The high price target for PLXP is $14.00 and the low price target for PLXP is $12.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.00$13.00$13.00$12.00
Price Target Upside: 217.07% upside152.43% upside113.11% upside93.55% upside

PLx Pharma (NASDAQ:PLXP) Consensus Price Target History

Price Target History for PLx Pharma (NASDAQ:PLXP)

PLx Pharma (NASDAQ:PLXP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2018Janney Montgomery ScottDowngradeBuy -> Neutral$14.00LowView Rating Details
8/1/2017Redburn PartnersUpgradeOutperformLowView Rating Details
7/31/2017UBSUpgradeMarket Perform -> Outperform$12.00HighView Rating Details
10/26/2016Raymond JamesDowngradeOutperform -> Mkt PerformN/AView Rating Details
10/25/2016Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

PLx Pharma (NASDAQ:PLXP) Earnings History and Estimates Chart

Earnings by Quarter for PLx Pharma (NASDAQ:PLXP)

PLx Pharma (NASDAQ:PLXP) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.63 EPS
Next Year EPS Consensus Estimate: $-1.35 EPS

PLx Pharma (NASDAQ PLXP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/23/2018Q4 2017($0.55)($0.48)$0.34 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.41)($0.44)$0.06 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.24)($0.54)$0.38 millionViewN/AView Earnings Details
4/17/2017Q1 2017($0.12)($0.14)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.45)($0.45)ViewN/AView Earnings Details
8/3/2016Q216($0.54)($0.52)ViewN/AView Earnings Details
5/11/2016Q116($0.52)($0.56)ViewListenView Earnings Details
3/22/2016Q4 2015($3.92)($4.32)ViewN/AView Earnings Details
11/13/2015Q315($0.47)($0.49)ViewListenView Earnings Details
8/13/2015Q215($0.43)($0.47)ViewListenView Earnings Details
5/14/2015Q115($0.44)($0.49)ViewListenView Earnings Details
4/14/2015($0.44)($0.38)ViewN/AView Earnings Details
3/24/2015Q414$0.52($0.38)ViewN/AView Earnings Details
11/12/2014Q3 2014($0.49)($0.45)ViewN/AView Earnings Details
8/12/2014Q2 2014($0.37)($0.46)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

PLx Pharma (NASDAQ:PLXP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

PLx Pharma (NASDAQ PLXP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 47.70%
Institutional Ownership Percentage: 24.60%
Insider Trading History for PLx Pharma (NASDAQ:PLXP)
Insider Trading History for PLx Pharma (NASDAQ:PLXP)

PLx Pharma (NASDAQ PLXP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2017David Emerson JordenCFOBuy32,727$6.88$225,161.76151,913View SEC Filing  
6/14/2017Gary L MossmanCOOBuy7,273$6.88$50,038.2478,255View SEC Filing  
6/14/2017Michael J ValentinoInsiderBuy29,091$6.88$200,146.08122,386View SEC Filing  
5/21/2014Jack H DeanDirectorBuy3,000$9.00$27,000.00View SEC Filing  
3/18/2014David GarrettVPBuy2,083$12.00$24,996.00View SEC Filing  
3/18/2014Thomas L HarrisonDirectorBuy2,000$12.00$24,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

PLx Pharma (NASDAQ PLXP) News Headlines

Source:
DateHeadline
PLx Pharma (PLXP) Lowered to "Sell" at Zacks Investment ResearchPLx Pharma (PLXP) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 8 at 10:35 AM
PLx Pharma Inc (PLXP) Given Average Recommendation of "Hold" by AnalystsPLx Pharma Inc (PLXP) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 9:08 AM
PLx Pharma (PLXP) Cut to Neutral at Janney Montgomery ScottPLx Pharma (PLXP) Cut to Neutral at Janney Montgomery Scott
www.americanbankingnews.com - March 26 at 9:04 AM
PLx Pharma (PLXP) Releases  Earnings Results, Beats Expectations By $0.07 EPSPLx Pharma (PLXP) Releases Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - March 25 at 5:35 PM
PLx Pharmas (PLXP) CEO Natasha Giordano on Q4 2017 Results - Earnings Call TranscriptPLx Pharma's (PLXP) CEO Natasha Giordano on Q4 2017 Results - Earnings Call Transcript
www.msn.com - March 23 at 5:41 PM
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 ResultsPLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - March 23 at 8:19 AM
PLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference CallPLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call
finance.yahoo.com - March 15 at 6:11 PM
PLx Pharma Inc (PLXP) Given Consensus Recommendation of "Hold" by BrokeragesPLx Pharma Inc (PLXP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 2:13 PM
PLx Pharma Inc (PLXP) Receives Average Rating of "Hold" from BrokeragesPLx Pharma Inc (PLXP) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 13 at 11:48 AM
Contrasting PLx Pharma (PLXP) & The CompetitionContrasting PLx Pharma (PLXP) & The Competition
www.americanbankingnews.com - January 23 at 3:24 AM
PLx Pharma (PLXP) Now Covered by Janney Montgomery ScottPLx Pharma (PLXP) Now Covered by Janney Montgomery Scott
www.americanbankingnews.com - January 20 at 7:38 PM
Analyst Actions: PLx Pharma Initiated by Janney With Buy Rating, $14/Share Price TargetAnalyst Actions: PLx Pharma Initiated by Janney With Buy Rating, $14/Share Price Target
www.nasdaq.com - January 19 at 5:12 PM
PLx Pharma Inc (PLXP) Receives Average Recommendation of "Hold" from BrokeragesPLx Pharma Inc (PLXP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 19 at 10:32 AM
Critical Review: PLx Pharma (PLXP) vs. Its CompetitorsCritical Review: PLx Pharma (PLXP) vs. Its Competitors
www.americanbankingnews.com - January 14 at 11:06 PM
Brokerages Expect PLx Pharma Inc (PLXP) to Announce ($0.51) EPSBrokerages Expect PLx Pharma Inc (PLXP) to Announce ($0.51) EPS
www.americanbankingnews.com - January 6 at 3:20 AM
PLx Pharma (PLXP) and Its Peers Head-To-Head AnalysisPLx Pharma (PLXP) and Its Peers Head-To-Head Analysis
www.americanbankingnews.com - December 29 at 3:28 AM
 PLx Pharma Inc (PLXP) Receives Average Recommendation of "Buy" from Analysts PLx Pharma Inc (PLXP) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 17 at 1:50 AM
Comparing Ascendis Pharma A/S (ASND) & PLx Pharma (PLXP)Comparing Ascendis Pharma A/S (ASND) & PLx Pharma (PLXP)
www.americanbankingnews.com - December 16 at 1:32 PM
 PLx Pharma Inc (PLXP) Receives Consensus Rating of "Buy" from Analysts PLx Pharma Inc (PLXP) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 11 at 1:36 PM
PLx Pharma (PLXP) Lifted to Sell at ValuEnginePLx Pharma (PLXP) Lifted to Sell at ValuEngine
www.americanbankingnews.com - December 4 at 9:38 PM
 Brokerages Set $12.00 Target Price for Dipexium Pharmaceuticals, Inc. (PLXP) Brokerages Set $12.00 Target Price for Dipexium Pharmaceuticals, Inc. (PLXP)
www.americanbankingnews.com - November 26 at 3:40 PM
Is PLx Pharma Inc’s (PLXP) Balance Sheet Strong Enough To Weather A Storm?Is PLx Pharma Inc’s (PLXP) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 22 at 6:43 AM
Dipexium Pharmaceuticals, Inc. (PLXP) Cut to Sell at Zacks Investment ResearchDipexium Pharmaceuticals, Inc. (PLXP) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 18 at 8:18 PM
Zacks: Analysts Set $12.00 Target Price for Dipexium Pharmaceuticals, Inc. (PLXP)Zacks: Analysts Set $12.00 Target Price for Dipexium Pharmaceuticals, Inc. (PLXP)
www.americanbankingnews.com - November 13 at 3:03 PM
PLx Pharma Inc. Reports Third Quarter 2017 ResultsPLx Pharma Inc. Reports Third Quarter 2017 Results
finance.yahoo.com - November 12 at 11:44 AM
PLx Pharma reports 3Q lossPLx Pharma reports 3Q loss
finance.yahoo.com - November 12 at 11:44 AM
PLx Pharma, Inc. to Host Earnings CallPLx Pharma, Inc. to Host Earnings Call
finance.yahoo.com - November 12 at 11:44 AM
PLx Pharma Inc. to Discuss 2017 Third Quarter Financial Results on November 10, 2017 Conference CallPLx Pharma Inc. to Discuss 2017 Third Quarter Financial Results on November 10, 2017 Conference Call
finance.yahoo.com - November 4 at 8:55 AM
Dipexium Pharmaceuticals, Inc. (PLXP) Upgraded at Zacks Investment ResearchDipexium Pharmaceuticals, Inc. (PLXP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 15 at 12:16 PM
 Dipexium Pharmaceuticals, Inc. (PLXP) Given Consensus Rating of "Buy" by Brokerages Dipexium Pharmaceuticals, Inc. (PLXP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 14 at 2:18 AM
Dipexium Pharmaceuticals (PLXP) & ZIOPHARM Oncology (ZIOP) Head-To-Head ComparisonDipexium Pharmaceuticals (PLXP) & ZIOPHARM Oncology (ZIOP) Head-To-Head Comparison
www.americanbankingnews.com - October 2 at 8:14 PM
PLx Pharma Present at the Sidoti & Company Fall 2017 ConferencePLx Pharma Present at the Sidoti & Company Fall 2017 Conference
finance.yahoo.com - September 19 at 6:33 AM
PLx Pharma Retains Dr. Efthymios N. Deliargyris as Chief Medical AdvisorPLx Pharma Retains Dr. Efthymios N. Deliargyris as Chief Medical Advisor
finance.yahoo.com - September 13 at 7:49 AM
Head-To-Head Survey: Dipexium Pharmaceuticals (PLXP) and Kindred Biosciences (KIN)Head-To-Head Survey: Dipexium Pharmaceuticals (PLXP) and Kindred Biosciences (KIN)
www.americanbankingnews.com - August 21 at 4:24 PM
PLx Pharma Inc. Reports Second Quarter 2017 ResultsPLx Pharma Inc. Reports Second Quarter 2017 Results
finance.yahoo.com - August 11 at 7:36 AM
PLx Pharma reports 2Q lossPLx Pharma reports 2Q loss
finance.yahoo.com - August 11 at 7:36 AM
Dipexium Pharmaceuticals, Inc. (PLXP) Rating Increased to Outperform at Redburn PartnersDipexium Pharmaceuticals, Inc. (PLXP) Rating Increased to Outperform at Redburn Partners
www.americanbankingnews.com - August 1 at 3:56 PM
Dipexium Pharmaceuticals, Inc. (PLXP) Upgraded by Raymond James Financial, Inc. to "Outperform"Dipexium Pharmaceuticals, Inc. (PLXP) Upgraded by Raymond James Financial, Inc. to "Outperform"
www.americanbankingnews.com - July 31 at 5:30 PM
UBS AG Upgrades Dipexium Pharmaceuticals, Inc. (PLXP) to "Outperform"UBS AG Upgrades Dipexium Pharmaceuticals, Inc. (PLXP) to "Outperform"
www.americanbankingnews.com - July 31 at 4:28 PM
 Dipexium Pharmaceuticals, Inc. (PLXP) Receives Consensus Rating of "Hold" from Analysts Dipexium Pharmaceuticals, Inc. (PLXP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 24 at 8:22 PM
Money Makers: Houston pharma co., construction company file multimillion-dollar raisesMoney Makers: Houston pharma co., construction company file multimillion-dollar raises
www.bizjournals.com - July 8 at 11:46 PM
Protalix BioTherapeutics (PLX) CEO Moshe Manor on Q1 2017 Results - Earnings Call TranscriptProtalix BioTherapeutics' (PLX) CEO Moshe Manor on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 8:18 AM
BRIEF-Rita OConnor appointed CFO of PLx PharmaBRIEF-Rita O'Connor appointed CFO of PLx Pharma
www.reuters.com - May 2 at 5:04 PM
PLx Pharma Inc. (PLXP) Names Rita O’Connor as CFOPLx Pharma Inc. (PLXP) Names Rita O’Connor as CFO
www.streetinsider.com - May 2 at 5:04 PM

SEC Filings

PLx Pharma (NASDAQ:PLXP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

PLx Pharma (NASDAQ:PLXP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

PLx Pharma (NASDAQ PLXP) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.